The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2.
